As of November 6, 2026, Aquestive Therapeutics, Inc. is a publicly traded company (Nasdaq: AQST); its largest reported holder is Bass Edward P, with 7.5% on Schedule 13G of October 7, 2026, then BlackRock (6.4%). The largest insider holding is Schobel Alexander Mark, the chief innovation and tech officer, with 980,726 shares (0.78% of shares outstanding), per Form 4/A of October 2, 2024 (Schedule 13G, October 7, 2026).
Is this your company?
About to sign with, pay or invest in Aquestive Therapeutics, Inc.? See the free Snapshot first.
Free to see. No signup.
Is Aquestive Therapeutics, Inc. a real, registered company?
- Aquestive Therapeutics, Inc. files with the SEC under CIK 1398733 (its SEC filings).
- Its shares are listed under the ticker AQST on Nasdaq (SEC company record).
- Incorporated in Delaware; business address in Warren, New Jersey, as its SEC filings state.
- Court and bankruptcy records: see Before you sign or pay below.
Before you sign or pay
- Court and bankruptcy: No federal court case or bankruptcy filing found under Aquestive Therapeutics, Inc. in our court records and SEC 8-K records (as of 2026-11-06).
- Leadership changes: the latest reported is Richard J. Daly, Director (Form 8-K filed 2026-09-29). Check you are dealing with the people now in charge.
- Ownership: 5%+ holders are reported on Schedule 13D or 13G; the latest names Bass Edward P (filed 2026-10-07).
Who are Aquestive Therapeutics, Inc.'s owners and officers?
Aquestive Therapeutics, Inc.: incorporated in Delaware; business address in Warren, New Jersey; industry Pharmaceutical Preparations (Schedule 13G, 2026-10-07).
| Report | Holder | Share |
|---|---|---|
| Schedule 13G, 2026-10-07 | Bass Edward P | 7.5% |
| Schedule 13G/A, 2026-10-07 | Bratton Douglas K | 0.6% |
| Schedule 13G/A, 2026-07-27 | Blackrock, Inc. | 6.4% |
| Schedule 13G, 2025-11-14 | Rtw Investments, LP | 5.2% |
| Schedule 13G/A, 2025-10-17 | Blackrock, Inc. | 5.3% |
Questions about who owns Aquestive Therapeutics, Inc.
Who owns Aquestive Therapeutics, Inc.?
On this page, 3 holders' latest ownership filings report 5% or more of Aquestive Therapeutics, Inc.: Bass Edward P (7.5%, Schedule 13G, filed 2026-10-07), Blackrock, Inc. (6.4%, Schedule 13G/A, filed 2026-07-27) and Rtw Investments, LP (5.2%, Schedule 13G, filed 2025-11-14).
Who are the largest shareholders of Aquestive Therapeutics, Inc.?
By the share each holder's latest filing reports, the largest holders of Aquestive Therapeutics, Inc. on this page are Bass Edward P (7.5%), Blackrock, Inc. (6.4%) and Rtw Investments, LP (5.2%).
When did Bass Edward P buy into Aquestive Therapeutics, Inc.?
The filings give report dates, not purchase dates. The earliest filing from Bass Edward P on this page is the Schedule 13G, filed 2026-10-07, reporting 7.5%.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 5 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Want the whole picture on Aquestive Therapeutics, Inc.?
Example from a real report (our sample on Target): “Target eliminated approximately 1,800 corporate positions, with around 1,000 employees receiving layoff notices and the remainder accounted for by eliminating open roles.” Source: NBC News
A Full Report on Aquestive Therapeutics, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Aquestive Therapeutics, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
12 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
| Filed | Person | Role | Change | Effective |
|---|---|---|---|---|
| Form 8-K, 2026-09-29 | Richard J. Daly | Director | appointed | 2026-10-14 |
Which insiders own Aquestive Therapeutics, Inc. shares?
Directors, officers and holders of 10% or more report their shares on Forms 3, 4 and 5. Each line is the latest such report, largest holding first.
- , the chief innovation and tech officer: 980,726 shares (0.78% of shares outstanding) (Form 4/A, 2024-10-02).
- , the chief executive and president: 627,317 shares (0.50% of shares outstanding) (Form 4, 2026-10-16).
- , the chief science officer: 343,552 shares (0.27% of shares outstanding) (Form 4, 2025-03-11).
- , the chief people officer: 284,024 shares (0.23% of shares outstanding) (Form 4, 2026-09-10).
- , the chief financial officer: 283,460 shares (0.23% of shares outstanding) (Form 4, 2026-05-07).
Shares outstanding: 125,687,705 as of 2026-10-30, from the company's latest SEC cover page.
How much has Aquestive Therapeutics, Inc. raised?
No fundraising or offering filing from Aquestive Therapeutics, Inc. is on file with us.
Keep reading
More on Aquestive Therapeutics, Inc. and the records around it.
Aquestive Therapeutics, Inc. elsewhere on the record
- 5%+ stake filings Oct 2026
- Leadership changes Sep 2026
Companies that share a holder
- RTW Investments, LP also filed stake reports on 43 other companies: CG Oncology, Inc. (Aug 2026), iRhythm Holdings, Inc. (Aug 2026), Kailera Therapeutics, Inc. (Aug 2026)
- BlackRock, Inc. also filed stake reports on 1596 other companies: AvePoint, Inc. (Nov 2026), BIOMARIN PHARMACEUTICAL INC (Nov 2026), MSG RANGERS CORP (Nov 2026)
Related pages
Filings, cases and notices link to their records. A not-found line names the records searched; it is not proof of absence.
Not for employment, credit, insurance or tenancy decisions.
Cite this page
https://mentionfox.com/who-owns/aquestive-therapeutics